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Introduction
Breast cancer is the most commonly diagnosed cancer in 
the UK, with more than 45,000 new cases per year, and a 
lifetime risk of 1 in 9 [1]. Incidence rates have risen over 
the past 20 years in industrialised countries, but the same 
period has seen the development of many new treat-
ments, and eight out of ten women diagnosed with breast 
cancer are now expected to survive 5 years or more [1,2]. 
Th   e improvements in treatment include novel cytotoxic 
drugs and many targeted agents, such as trastuzumab, 
lapatinib and the aromatase inhibitors.
Within the past 5 years, it has become apparent that 
another powerful class of agents - the poly(ADP-ribose) 
polymerase (PARP) inhibitors - has activity in deﬁ  ned 
groups of patients with breast cancer [3-11]. Th  ese  agents 
target a DNA repair pathway via a novel mechanism of 
action that can be exploited to the beneﬁ  t of patients 
with breast cancer. Th  is review will brieﬂ  y discuss the 
development of PARP inhibitors, and the data supporting 
their potential clinical use in breast cancer, as single 
agents and in combination with chemotherapy.
PARP activity and inhibition
Th   e PARP family of enzymes was ﬁ  rst described over 40 
years ago [12]. PARP1 and PARP2 occur in the cell 
nucleus, and are activated by DNA damage [13]. PARP1, 
the most abundant form of the enzyme [14], acts as a 
‘molecular nick sensor’ to signal DNA single-strand 
breaks (SSBs) and assist in their repair [15]. It is inactive 
until bound to a DNA strand break via its zinc ﬁ  nger 
DNA-binding domain. After binding, PARP1 uses NAD+
to form long, branched polymers of poly(ADP-ribose) on 
acceptor proteins, including PARP itself. Th  is auto-
poly(ADP-ribosyl)ation creates a negatively charged 
target at the SSB, which recruits the enzymes required to 
form the base excision repair multi-protein complex 
[16,17]. Following ADP-ribosylation, PARP1 has reduced 
aﬃ   nity for DNA; it is released, opening up the chromatin 
and allowing access to the damaged site for the other 
repair complex proteins. Subsequently, the enzyme 
poly(ADP-ribose) glycohydrolase (PARG) removes the 
poly(ADP-ribose) polymer from PARP, allowing the 
enzyme to be recycled and reactivated at other areas of 
DNA damage (Figure 1).
Most of the PARP inhibitors currently undergoing 
clinical investigation have been designed to compete with 
NAD+ for its substrate binding site [18]. It is likely that 
these drugs inhibit both PARP1 and PARP2 [18]. 
Inhibition of PARP1 compromises a cell’s ability to over-
come damage to the genome by repairing DNA SSBs. 
Many commonly used anticancer treatments, such as 
radio  therapy, alkylating agents and camptothecins, 
damage DNA by causing SSBs, and prevention of SSB 
repair has been shown in preclinical studies to improve 
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developed as radio- or chemo-potentiating agents [20,21], 
the aim being to overcome cancer cell resistance to a 
DNA-damaging agent by preventing repair of the poten-
tially lethal damage to the cancer cell caused by the 
treatment.
Potent PARP inhibitors ﬁ  rst entered early clinical trials 
in 2003 [22], and there has been rapid expansion of the 
ﬁ  eld in the past 5 years. Several PARP inhibitors are being 
investigated for a range of indications [23,24], mainly 
cancers (Table 1). Early clinical studies suggest that PARP 
inhibitors will have a role in the treatment of breast 
cancer, with promising data emerging from trials in two 
speciﬁ  c areas: hereditary BRCA-deﬁ  cient breast cancer 
(single-agent PARP inhibition) and triple-negative breast 
cancer (TNBC; PARP inhibition in combination with 
chemotherapy) [3-6,7-11]. However, with improved 
understanding of the mechanisms of PARP1 inhibition in 
these two clinical scenarios, it is likely that a wider group 
of patients with breast cancer may also beneﬁ  t from this 
approach to treatment.
Single-agent PARP inhibitors in hereditary BRCA-
defi  cient cancer
Th  e publication in 2005 of paired pre-clinical papers in 
Nature, demonstrating hypersensitivity of BRCA-deﬁ  -
cient cancer cells to single-agent PARP inhibitors, opened 
the door to clinical research into these agents as mono-
therapy [25,26], and provided the clearest demonstration 
to date of a class eﬀ   ect. Before this ground-breaking 
research was published, it had been argued that PARP 
inhibitors would have no activity when used alone, and 
drug developers were chasing the elusive goal of chemo-
potentiation in tumours without an increase in toxicity in 
normal tissue.
Initial preclinical experiments in cell lines and xeno-
grafts demonstrated that cells with loss of the 
homolo  gous recombination repair pathway for DNA 
double-strand breaks (DSBs) are hypersensitive to block-
ade of SSB repair with a PARP inhibitor. Th   e key to this 
mechanism of action is the role that BRCA1 and BRCA2 
play in signalling DSBs (BRCA1) and the repair of such 
breaks via the homologous recombination pathway 
(BRCA2) [27].
Th   e proposed mechanism for the cytotoxicity of PARP 
inhibition is that blockade of SSB repair leads to the 
formation of unrepaired DSBs at the replication fork. In 
normal or BRCA-heterozygous cells, the lesion can be 
repaired by DSB mechanisms, and DNA replication and 
cell division continue. However, in cells that lack 
functional DSB repair, such as those with a homozygous 
mutation in BRCA1 or BRCA2, loss of two DNA repair 
pathways causes synthetic lethality and cell death [25,26].
Th   is proposition was ﬁ  rst tested clinically in a phase I 
study of AZD2281 (olaparib), looking at its potential 
activity as a single agent [28]. Th  is study used an oral 
formulation of olaparib, and assessed the pharmaco-
kinetics and pharmacodynamics of doses ranging from 
10 mg daily for 2 out of 3 weeks to 600 mg twice daily on 
a continuous schedule. Nine of the 19 patients with con-
ﬁ  rmed  BRCA  mutations had a partial response to 
olaparib, representing a 47% response rate in this popu-
lation. No responses were seen in 37 patients who did not 
have a BRCA mutation. Th   e dose-limiting toxicities were 
myelosuppression and central nervous system side 
eﬀ  ects. Toxicities to normal tissue were similar in the 
BRCA-deﬁ  cient and normal populations. An increase in 
γH2AX foci was found in plucked eyebrow hair follicles 
6 hours after olaparib treatment, compared with baseline. 
Th  ese foci indicate accumulation of DNA DSBs, so the 
ﬁ   nding demonstrated a proof of mechanism of the 
process of synthetic lethality, whereby preservation of 
SSBs by PARP inhibition leads to the formation of DNA 
DSBs in the absence of an external DNA-damaging agent. 
Figure 1. Mechanism of PARP1-mediated DNA repair. ARH3, ADP-ribosyl acceptor hydrolase 3; LigIII, DNA ligase III; PARG, poly(ADP-ribose) 
glycohydrolase; PARP, poly(ADP-ribose) polymerase; polβ, DNA polymerase; XRCC1, X-ray repair cross-complementing 1.
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was demonstrated in normal tissue, not in the tumour. It 
is not clear from the publication whether this pharmaco-
dynamic eﬀ   ect was seen in BRCA carriers with a 
heterozygote defect in all cells, or in all patient groups. 
Th   ese data, which suggest a risk of accumulation of DNA 
damage within normal tissue, raise concern over the 
potential dangers of prolonged, continuous dosing. In 
theory, there could also be an accumulation of tumouri-
genic mutations and second malignancies, so caution in 
the use of these agents in the adjuvant setting over 
prolonged periods may be advisable.
Th   e phase I ﬁ  ndings have been conﬁ  rmed by two phase 
II studies of olaparib in BRCA1 or BRCA2  mutation 
carriers in patients with breast [3,4] or ovarian [5,6] 
cancer previously treated with a median of three chemo-
therapy regimens. Both studies assessed response and 
toxicity in sequential cohorts of patients treated with 
400 mg twice daily or 100 mg twice daily. Th   e activity of 
olaparib as a single agent was conﬁ  rmed in the 400 mg 
cohorts, but there was less activity at the lower dose, 
suggesting that the extent of PARP inhibition is 
important for response. In the breast cancer study, 27 
patients with metastatic disease were treated at each 
dose, and the conﬁ  rmed response rate was 41% in those 
receiving the 400 mg schedule and 22% in the 100 mg 
cohort [3,4]. Toxicity was reduced with the lower dose, 
compared with the higher dose, but mild overall. Fatigue, 
nausea and vomiting were the commonest adverse events 
with this well tolerated agent.
A similar dose response was found in the phase II study 
of ovarian cancer, in which 33 patients were treated with 
olaparib 400 mg twice daily and 24 with 100 mg twice 
daily. Th   ere was a 33% conﬁ  rmed partial response rate at 
the higher dose and 13% at the lower dose [5,6]. 
Responses were seen in carriers of BRCA1  or  BRCA2 
muta  tions, and in patients with either platinum-sensitive 
or platinum-resistant disease. However, these results are 
not consistent with ﬁ  ndings from previous studies that 
acquired resistance to platinum-based treatment in 
ovarian cancer is associated with regain of BRCA func-
tion [29,30].
Th  e ﬁ  ndings of these small, non-randomised phase I 
and phase II studies require conﬁ  rmation at phase III. 
Meanwhile, they do provide the exciting suggestion that 
single-agent therapy with PARP inhibitors will be of 
beneﬁ  t in BRCA-positive patients, and oﬀ  er low toxicity. 
Phase II studies in this indication are ongoing with the 
PARP inhibitors PF01367338 (AG014699) and ABT-888 
(veliparib). A phase I single-agent study with the novel 
Table 1. PARP inhibitors under clinical investigation in malignant disease 
Agent (year entered    Single/combination
clinical research)  Manufacturer  therapy  Oral/intravenous  Clinical indication(s)  Status
AG014699, PF0367338 
(2003)
Pfi  zer (New York, NY, USA) Single agent; multiple 
combinations
Intravenous and 
oral
Solid tumours; 
melanoma; BRCA 
germline
Phase I and II melanoma 
studies complete. Phase II 
BRCA studies open
KU59436, AZD2281, 
olaparib (2005)
AstraZeneca/KuDOS 
(London, UK)
Single agent; multiple 
combinations
Oral Various, including BRCA 
germline
Phase I complete. 
Numerous phase II studies 
ongoing
ABT-888, veliparib 
(2006)
Abbott Laboratories 
(North Chicago, IL, USA)
Multiple combinations Oral Solid tumours; 
melanoma; lymphoid 
malignancies
Phase 0/I completed 
in some indications. 
Numerous phase II studies 
ongoing
BSI-201, SAR 240550, 
iniparib (2006)
BiPar (South San 
Francisco, CA, USA; Sanofi   
Aventis)
Combination with 
gemcitabine and 
carboplatin; temozolomide
Intravenous TNBC; lung cancer; 
glioma 
Phase II studies completed. 
Phase III study in TNBC 
recruiting. Phase II study in 
lung near completion
INO-1001 (2005/2006) Inotek/Genentech 
(Lexington, MA, USA)
Single agent; combination 
with temozolomide
Intravenous Melanoma; malignant 
glioma
Phase Ib in melanoma 
completed 
MK4827 (2008) Merck Sharp Dohme 
(Hoddesdon, UK)
Single agent; combination 
with chemotherapy
Oral Solid tumours; BRCA-
related ovarian cancer
Phase I ongoing
CEP-9722 (2009) Cephalon (Frazer, PA, USA) Single agent; combination 
with temozolomide
Oral Solid tumours Phase I ongoing
GPI 21016 (2010) MGI Pharma 
(Bloomington, MN, USA)
Combination with 
temozolomide
Oral Solid tumours Phase I ongoing
E7016 (2010) MGI Pharma 
(Bloomington, MN, USA), 
Eisai (Baltimore, MD, USA)
Combination with 
temozolomide
Oral Solid tumours Phase I ongoing
LT673 (2011) Lead Therapeutics/
Biomarin (Novato, CA, 
USA)
Single agent and 
combination planned
Oral Solid tumours Phase I planned
PARP, poly(ADP-ribose) polymerase; TNBC, triple-negative breast cancer.
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potential for activity with low toxicity in this group of 
patients [31].
PARP inhibitors as chemo-potentiating agents
As discussed above, PARP inhibitors were initially en-
visaged as chemo-potentiating agents. In previous 
studies, using inhibitors of methyl guanine methyl trans-
ferase to prevent DNA repair during cytotoxic therapy, 
the dose of chemotherapy needed to be reduced because 
of enhanced toxicity with the treatment combination 
[32-34]. Similarly, in some of the ﬁ  rst studies of PARP 
inhibitors in combination with chemotherapy, a higher 
level of myelosuppression was observed than would have 
been expected with the chemotherapeutic agent alone 
[7,22,35-37]. Two further studies required protocol 
amendments in light of dose-limiting toxicities associated 
with olaparib in combination with chemotherapy - in 
particular, myelosuppression [8,38]. Th  ese  ﬁ  ndings 
present two challenges to physicians and scientists 
designing trials with combinations of chemotherapy with 
PARP inhibitors. First, should clinical studies be designed 
with the maximum dose of chemotherapy possible, or a 
maximal dose of PARP inhibitor accepting a chemo-
therapy dose reduction? Th   e answer to this will lie in the 
clinical outcome data and also how the PARP inhibitor is 
being used - for its single agent activity or as a true 
chemo-potentiating agent. Second, there is a need to 
investigate the mechanism by which PARP inhibitors 
enhance damage to normal tissue when used with some 
of the agents reported (platinums, bifunctional alkylating 
agents such as cyclophosphamide or the antimetabolite, 
gemcitabine), where repair of cytotoxic damage is not 
thought to be achieved via a PARP-dependent mecha-
nism. Th   ere is one molecule in the class - BSI-201 (SAR 
240550, iniparib) - for which normal tissue toxicity 
appears to be less of an issue, and so far this is the PARP 
inhibitor that has progressed furthest in the clinic.
PARP inhibitors in triple-negative breast cancer
Following encouraging results with iniparib in combi-
nation with chemotherapy with various solid tumours 
[39], clinical investigators have gone on to study this agent 
with chemotherapy in TNBC, a disease with a bio  logical 
phenotype similar to BRCA1-defective cancers [40]. It 
must be borne in mind that iniparib may act via a 
diﬀ  erent mechanism to the PARP inhibitors discussed 
above, and does not appear to have the limitation of 
enhanced toxicity in normal tissue [39,41,42].
Evidence of an improvement in anti-tumour activity 
has been reported in patients previously treated with two 
or more cytotoxic regimens who received iniparib in 
combi  nation with carboplatin and gemcitabine, com-
pared with those who received the chemotherapy 
regimen alone [9]. In this phase II study, 123 patients 
with TNBC were randomised to receive carboplatin 
(AUC2) and gemcitabine (1,000 mg/m2) on days 1 and 8 
of a 21-day cycle, with or without iniparib 5.6 mg/kg on 
days 1, 4, 8 and 11. Th   e objective response rate was 52% 
in the iniparib group, compared with 32% in those who 
received chemotherapy alone (P = 0.02), median 
progression-free survival was 5.9 versus 3.6 months, 
respectively (P = 0.01), and overall survival was 12.3 
versus 7.7 months, respectively (P = 0.01) [9,10]. No 
diﬀ   er  ence was observed in the rate of adverse events 
between the two treatment groups. A phase III study of 
iniparib in combination with carboplatin and gemcita-
bine for the same indication was initiated in 2009, and 
rapidly completed recruitment. It is hoped that prelimi-
nary results will be reported at the American Society of 
Clinical Oncology (ASCO) 2011 meeting. However, 
initial indications from the manufacturer, Sanoﬁ  -Aventis, 
are that the phase III trial did not meet the primary 
endpoints of overall and progression-free survival [43].
It is possible that the intermittent dosing regimen used 
in the studies cited above helps to protect against 
enhanced myelosuppression and hence toxicity. However, 
if iniparib is acting as a PARP inhibitor, it is intriguing 
that this intermittent schedule also provides an increase 
in overall treatment eﬃ     cacy, compared with chemo-
therapy alone. It is possible that iniparib is acting as a 
single agent on the BRCA-like phenotype of TNBC, or 
that it is somehow able to prevent repair to treatment-
induced DNA damage within the tumour without 
increased damage to normal tissue. If they conﬁ  rm the 
phase II data, the results of the phase III study of iniparib 
and chemotherapy in TNBC may lead to an advance in 
the treatment of patients, but they will also present an 
intriguing puzzle to scientists working with PARP 
inhibitors.
It is also interesting to note that single-agent olaparib 
was described as having activity in TNBC at the ASCO 
2010 meeting [11]. Th   is was the ﬁ  rst trial to evaluate the 
eﬃ     cacy of a PARP inhibitor as a single agent for the 
treatment of sporadic TNBC, and responses were seen 
only in tumours that occurred on a background of 
BRCA1 germline mutation [11].
Conclusion
Research into PARP inhibition is beginning to show the 
potential of targeting DNA repair as a strategy in the 
development of new anti-cancer agents. Th   is is a class of 
drugs with activity as monotherapy and in combination 
with treatments that cause DNA damage [4,8,38]. It is 
very unusual in cancer therapy for a new drug to be used 
solely as monotherapy, and research to date suggests that 
PARP inhibitors are likely to be used also as components 
of combination regimens. Indeed, the single-agent and 
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present an interesting challenge to drug developers as we 
try to improve treatments for our patients. If we wish to 
exploit the single-agent activity of a PARP inhibitor as 
part of a combination regimen, we may need to consider 
scheduling PARP-based treatment separately to any 
DNA-damaging component of the combination. 
However, when using a PARP inhibitor as a chemo-
potentiator, concomitant treatment would be appropriate.
Th  e phase III trial of iniparib in TNBC is nearing 
completion. If the data conﬁ  rm the earlier ﬁ  ndings, it will 
provide a promising new treatment for this patient group. 
However, there remain many scientiﬁ  c questions about 
the underlying mechanism of action of iniparib in this 
setting, and the diﬀ  erences between the individual agents 
in the PARP inhibitor class.
Whatever the explanation, PARP inhibition may even-
tually oﬀ  er an eﬀ  ective treatment approach for patients 
with  BRCA-related breast cancer and TNBC, and the 
array of compounds in development will allow clinical 
investigators to exploit the diﬀ   erences to extend our 
scientiﬁ  c knowledge and thus beneﬁ  t a wider range of 
patients.
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